- Companies
- Artera
Artera Funding, Investors & Competitors
Artera has raised $110M across 2 funding rounds, most recently a $20M undisclosed-stage round in February 2024.
Last Artera funding round
$20M
Undisclosed stage · Feb 2024
Cumulative funding Artera raised
$110M
across 2 funding rounds
Key investors in Artera
Walden Catalyst
Coatue
Johnson & Johnson Innovation
Breyer Capital
EDBI
Marc Benioff
Koch Disruptive Technologies
Prosperity7 Ventures
About Artera
Artera is a Boston-based medical AI company developing software tests that analyze H&E histopathology images to predict cancer therapy responses and patient prognoses. Its platform integrates into routine clinical workflows, providing oncologists with personalized treatment insights without additional hardware. FDA-cleared for prostate and breast cancer applications, Artera collaborates with pathology labs and hospitals across the US and Europe. Founded in 2019, the company has validated its algorithms on datasets from over 10,000 patients, partnering with AstraZeneca for clinical trials.
Founded
2021
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Artera Funding History
Artera has raised a total of $110M across 2 funding rounds.
Artera's first fundraising round was a $90M undisclosed-stage round in March 2023. The most recent completed round was a $20M undisclosed-stage round in February 2024.
Artera funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Feb 2024 | Undisclosed stage | Navin Chaddha; Andrew Tan; Prosperity7 Ventures; EDBI; Rajiv Khemani; Walden Catalyst; AIspace Ventures; Wilson Sonsini Goodrich & Rosati | $20M | - |
| Mar 2023 | Undisclosed stage | Breyer Capital; Amarjit Gill; Clarence So; Koch Disruptive Technologies; Coatue; Breyer Labs; Marc Benioff; Walden Catalyst; Chris Re; Johnson & Johnson Innovation; Dennis Wong | $90M | Artera is a San Francisco-based precision medicine company developing multimodal artificial intelligence-based predictive and prognostic cancer tests to personalize therapy for cancer patients. The company was founded in late 2021 and launched publicly in March 2023 with its flagship ArteraAI Prostate Test, the first test to predict therapy benefits in localized prostate cancer. The test combines digital pathology and clinical data to deliver individualized treatment recommendations and is clinically available through a CLIA-certified laboratory in Jacksonville, Florida. Artera raised $90 million in Series A funding in March 2023 from a syndicate of prominent tech and healthcare investors including institutional investors Coatue, Johnson & Johnson Innovation (JJDC Inc.), Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, and The Factory, alongside 11 angel investors including Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, and Michael Driscoll. The company stated it had steered clear of Silicon Valley Bank and was in a healthy financial position focused on capital efficiency. The funding announcement came on the heels of Artera's positive data from ASCO GU 2023, demonstrating that the prognostic biomarker was validated across six phase III randomized trials, showing the multimodal AI biomarker's ability to enable personalized, shared decision-making for patients and clinicians. The fresh capital was earmarked to finance commercial distribution of the prostate cancer test in the United States and globally, as well as to develop tests supporting therapy personalization for other cancer types. Following the initial round, Artera raised an additional $20 million in Series B funding in February 2024 backed by Prosperity7 Ventures, bringing total capital raised to $110 million by that date. |
Who has invested in Artera?
18 investors have backed Artera across its funding rounds, including Walden Catalyst, Coatue, Johnson & Johnson Innovation, Breyer Capital, EDBI and Marc Benioff.
Artera Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Participant | Mar 2023 | ||
| 1 | Participant | Feb 2024 | ||
| 1 | Participant | Mar 2023 | ||
| 1 | Participant | Feb 2024 | ||
| 1 | Participant | Mar 2023 | ||
| 1 | Participant | Mar 2023 | ||
| 1 | Participant | Feb 2024 | ||
| 1 | Participant | Mar 2023 | ||
| 1 | Participant | Feb 2024 | ||
| 1 | Participant | Feb 2024 | ||
| 1 | Participant | Mar 2023 | ||
| 1 | Participant | Mar 2023 | ||
| 1 | Participant | Mar 2023 | ||
This data is available for Pro users. Sign up to see all 18 Artera investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialArtera Competitors
Artera competitors include listed companies like GE HealthCare, Pro Medicus and United Imaging, and private ones like ConcertAI, United Imaging Intelligence and Viz.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $200M | - | $1.9B | 9.5x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $186M | $147M | $13B | 62.7x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Private | - | - | $1.4B | - | ||
| Private | $100M | - | $1.3B | 12.8x |
Artera Public Comps
Artera is still privately-owned, but its public comps include CrowdStrike, SAP, Salesforce, ServiceNow, Adobe, Datadog, Moody's, Natera, Workday and IQVIA.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $4.8B | ($12M) | 51.4x | 44.5x | (19816.2x) | 151.0x | |||
| $42B | $13B | 5.8x | 5.4x | 18.4x | 17.1x | |||
| $42B | $13B | 5.5x | 5.2x | 17.8x | 12.2x | |||
| $13B | $2.6B | 11.1x | 9.6x | 57.2x | 25.0x | |||
| $24B | $9.3B | 4.3x | 3.9x | 10.9x | 8.2x | |||
| $3.4B | ($588K) | 23.6x | 19.4x | (137813.0x) | 77.6x | |||
| $7.7B | $3.8B | 11.2x | 10.6x | 22.5x | 20.1x | |||
| $2.3B | ($266M) | 22.5x | 19.0x | (195.0x) | (261.5x) | |||
This data is available for Pro users. Sign up to see all Artera competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Artera
| When was Artera founded? | Artera was founded in 2021. |
| Where is Artera headquartered? | Artera is headquartered in San Francisco, CA, United States. |
| Is Artera publicly listed? | No, Artera is a private, VC-backed company. |
| How much funding has Artera raised? | Artera has raised $110M across 2 funding rounds. |
| What was Artera's last funding round? | Artera's last funding round was a $20M undisclosed-stage round in February 2024. |
| Who are Artera's investors? | Artera's investors include Walden Catalyst, Navin Chaddha, Breyer Capital, Andrew Tan, Amarjit Gill, Clarence So, Prosperity7 Ventures, Koch Disruptive Technologies, EDBI, Rajiv Khemani and 8 others. |
| Which companies are comparable to Artera? | Companies comparable to Artera include ConcertAI, GE HealthCare, Pro Medicus, United Imaging, United Imaging Intelligence and Viz. |
See companies similar to Artera
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




